Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals.

Indian heart journal - 1 Jan 2000

Yadav Anshu Kumar, Chakkumkollath Aparna Kodakkat, Helna Aysha, Birla Siddharth, Thimmulappa Rajesh Kumar, Shambu Sunil Kumar, Vishwanath Prashant, Prashant Akila

Abstract excerpt

BACKGROUND: It is essential to investigate the prevalence of CYP2C19 alleles that affect drug metabolism. This study measures the allelic and genotypic frequencies of CYP2C19 loss-of-function (LoF) alleles CYP2C19∗2, CYP2C19∗3, and gain-of-function (GoF) alleles CYP2C19∗17 in the general population. METHODOLOGY: The study involved 300 healthy subjects between the ages of 18 and 85 recruited by simple random...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Clopidogrel

Share to Cytochrome P-450 CYP2C19

Share to Gene Frequency

Share to Platelet Aggregation Inhibitors

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 37217095
DOI: 10.1016/j.ihj.2023.05.005
PMCID: PMC10568051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals.PMID 37217095Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Semantic proximity Read ↗

Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from north-western China.Semantic proximity Read ↗

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives.Semantic proximity Read ↗

CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugsSemantic proximity Read ↗

Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant.Semantic proximity Read ↗

Clopidogrel PharmacogeneticsSemantic proximity Read ↗

Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?Semantic proximity Read ↗

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practiceSemantic proximity Read ↗

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.Semantic proximity Read ↗

Study on the effect of CYP2C19 genetic polymorphism and plasma concentration on clopidogrel resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.